RESOURCES / BLOG

What the 2027 Medicare Outpatient Payment Proposal Means for Hospital Revenue Cycles

The CY 2027 OPPS proposed rule introduces 340B rate revisions, imaging site-neutral expansion, and an accelerated nondrug payment recovery. Here is what your revenue cycle team should do before January 2027.
Inger Sivanthi
Inger Sivanthi
Chief Executive Officer · Published Jul 21, 2026
SHARE
2027 Medicare Outpatient Payment Proposal

Table of Contents

  • Base rate increase is 2.4%, but net impact averages 1.9% because budget neutrality adjustments, the 340B remedy offset, and site-neutral policy changes reduce the actual payment update most hospitals receive.
  • 340B drug payment rates shift significantly, moving from ASP+6% to ASP-33.4%, so hospitals with high 340B drug utilization should model this change against their specific drug mix and volume now.
  • Imaging-without-contrast services at off-campus HOPDs move to physician fee schedule rates, covering key APCs including ultrasound, CT, and MRI composites, with rural sole community hospitals exempt.
  • The nondrug payment recovery accelerates from 0.5% to 3% per year through 2027–2029, covering $7.8 billion in prior excess payments, and hospitals should account for this across their highest-volume outpatient APCs.
  • The comment deadline is August 31, 2026, and the final rule publishes in November 2026, giving revenue cycle leaders a defined window to engage, model final numbers, and update workflows before January 1, 2027.

On July 2, 2026, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS). This rule touches nearly every corner of how hospitals get paid for outpatient care. If you run a hospital revenue cycle, manage outpatient billing, or lead hospital finance operations, you need to understand exactly what CMS is proposing and how it could affect your healthcare operations. 

What the 2027 OPPS Proposed Rule Actually Changes

CMS proposes a 2.4% base payment increase for 2027, but several payment adjustments within this rule reduce the net benefit for many hospitals. This rule is one of the most consequential OPPS updates in recent years, because CMS uses it to advance several policy objectives at once, not just adjust rates. 

Here is what the rule proposes in plain terms: 

  • A 2.4% base rate increase, derived from a 3.2% market basket update minus a 0.8% productivity adjustment 
  • A revised 340B drug payment rate, moving from ASP+6% to ASP-33.4% 
  • A 3% offset on nondrug payments to recover excess payments made from 2018-2022 
  • Site-neutral payment expansion to imaging-without-contrast services at off-campus HOPDs 
  • Phase two of the inpatient-only (IPO) list removal, with 638 more procedures coming off 
  • Eight new prior authorization codes added for botulinum toxin injections 
  • A request for information on hospital price transparency standards 

Hospitals with significant 340B drug programs will want to model the financial impact carefully, as the net payment change varies based on each hospital’s service and drug mix. 

The 340B Drug Payment Rate Revision and What It Means for Revenue Cycle Teams

CMS proposes adjusting the Medicare Part B payment rate for 340B-acquired drugs from ASP+6% to ASP-33.4%. That is a substantial revision, and revenue cycle leaders need to understand both the reasoning behind it and its financial implications. 

Why CMS Is Proposing This Rate Change

he Supreme Court’s 2022 ruling in American Hospital Association v. Becerra addressed the previous 2018-2022 340B payment rates, and it indicated that rate adjustments based on actual drug acquisition cost survey data could be permissible. CMS conducted a survey in Q1 2026 and used those findings to support this proposed rate revision. 

Survey participation covered roughly 1,300 hospitals, representing 41.4% of eligible hospitals and 28.6% of all 340B hospitals. Some industry groups have raised questions about whether broader participation would produce the same findings, and the comment process gives hospitals an opportunity to weigh in on the methodology. 

On the industry response side, Jennifer DeCubellis, president and CEO of America’s Essential Hospitals, has called for a more thorough review of the data, noting that essential hospitals depend significantly on 340B program benefits. Premier Inc.’s vice president for advocacy, John Knapp, has also called for CMS to weigh the full financial picture for hospitals before finalizing the rate. 

The Financial Breakdown

Metric Estimated Impact
First-year Medicare drug payment savings for CMS $4.55 billion
First-year beneficiary cost-sharing reduction $1.15 billion
Hospitals represented in survey data ~28.6% of all 340B hospitals
Budget neutrality nondrug payment offset Partially positive for low-340B hospitals
Hospitals with lower 340B drug utilization may see a benefit from this change, because budget neutrality requires CMS to increase nondrug payment rates to offset the drug payment revision.

Hospitals that rely more heavily on 340B savings should factor this rate change into their 2027 financial planning now.

When comparing eligibility verification software, speed matters, but it should not be the only deciding factor. Most practices can already confirm whether coverage is active. The real value is in how much useful information the platform provides, including copays, deductibles, coinsurance, visit limits, coverage restrictions, and possible prior authorization requirements. 

A strong platform should also catch incorrect member details, missing information, and incomplete payer responses. More importantly, it should reduce the portal searches, payer calls, exception reviews, and manual updates that often follow the first eligibility check. Those practical workflow needs are the standard used to compare the five platforms in this article. 

When comparing eligibility verification software, speed matters, but it should not be the only deciding factor. Most practices can already confirm whether coverage is active. The real value is in how much useful information the platform provides, including copays, deductibles, coinsurance, visit limits, coverage restrictions, and possible prior authorization requirements. 

A strong platform should also catch incorrect member details, missing information, and incomplete payer responses. More importantly, it should reduce the portal searches, payer calls, exception reviews, and manual updates that often follow the first eligibility check. Those practical workflow needs are the standard used to compare the five platforms in this article. 

The 340B Remedy Offset and the Accelerated Recovery Timeline

Separate from the 340B drug payment rate revision, CMS also proposes accelerating the recovery of $7.8 billion in nondrug payments that were made to hospitals during 2018-2022. 

Here is the context. During 2018 through most of 2022, CMS applied lower 340B drug payment rates while also adjusting nondrug payments upward through budget neutrality to keep overall payments balanced. Following the Supreme Court’s 2022 ruling, CMS provided a remedy to affected hospitals. As part of that resolution, CMS also needs to recover the corresponding nondrug payment amounts that were part of the original budget neutrality adjustment. 

CMS originally structured that recovery over 16 years at 0.5% per year starting in 2026. The new proposal compresses that into three years at 3% per year from 2027 through 2029, completing the recovery by late 2029. 

For revenue cycle planning purposes, hospitals will see a 3% nondrug payment adjustment in 2027, and it is important to account for this across your highest-volume outpatient APCs. 

When comparing eligibility verification software, speed matters, but it should not be the only deciding factor. Most practices can already confirm whether coverage is active. The real value is in how much useful information the platform provides, including copays, deductibles, coinsurance, visit limits, coverage restrictions, and possible prior authorization requirements. 

A strong platform should also catch incorrect member details, missing information, and incomplete payer responses. More importantly, it should reduce the portal searches, payer calls, exception reviews, and manual updates that often follow the first eligibility check. Those practical workflow needs are the standard used to compare the five platforms in this article. 

When comparing eligibility verification software, speed matters, but it should not be the only deciding factor. Most practices can already confirm whether coverage is active. The real value is in how much useful information the platform provides, including copays, deductibles, coinsurance, visit limits, coverage restrictions, and possible prior authorization requirements. 

A strong platform should also catch incorrect member details, missing information, and incomplete payer responses. More importantly, it should reduce the portal searches, payer calls, exception reviews, and manual updates that often follow the first eligibility check. Those practical workflow needs are the standard used to compare the five platforms in this article. 

Site-Neutral Payment Expansion to Imaging Services

CMS proposed site-neutral payment for clinic visits in 2019 and extended the policy to drug administration services in 2026. For 2027, it proposes adding imaging-without-contrast services to the list. 

What Services Are Affected

When imaging-without-contrast procedures are performed at off-campus hospital outpatient departments (HOPDs), CMS would reimburse them at the physician fee schedule rate, roughly 40% of the full OPPS rate. The affected ambulatory payment classifications include: 

  • APCs 5521-5524 (imaging without contrast) 
  • APC 8004 (Ultrasound Composite) 
  • APC 8005 (CT and CTA without Contrast Composite) 
  • APC 8007 (MRI and MRI without Contrast Composite) 

Rural sole community hospitals are exempt from this adjustment. 

When comparing eligibility verification software, speed matters, but it should not be the only deciding factor. Most practices can already confirm whether coverage is active. The real value is in how much useful information the platform provides, including copays, deductibles, coinsurance, visit limits, coverage restrictions, and possible prior authorization requirements. 

A strong platform should also catch incorrect member details, missing information, and incomplete payer responses. More importantly, it should reduce the portal searches, payer calls, exception reviews, and manual updates that often follow the first eligibility check. Those practical workflow needs are the standard used to compare the five platforms in this article. 

The Projected Financial Impact

Savings Category 2027 Projected Amount
Medicare program savings $190 million
Beneficiary premium savings $70 million
Beneficiary cost-sharing savings $70 million

What to Look for Before Choosing Eligibility Verification Software

CMS’s position is that patients receiving a routine MRI at an off-campus HOPD should pay similar cost-sharing to what they would pay at a standalone imaging center. The American Hospital Association has noted in response that off-campus HOPDs often serve patients with more complex medical needs, and that the clinical context differs from a standard physician office or freestanding imaging facility. 

The Inpatient-Only List Continues to Evolve

CMS began phasing out the Inpatient-Only (IPO) list three years ago, and 2027 marks year two of its planned three-year transition. This year, 638 procedures move off the list, following 285 removed in 2026. 

The affected procedure categories include: 

  • Digestive system procedures 
  • Respiratory system procedures 
  • Urinary system procedures 
  • Maternity and delivery procedures 
  • Endocrine procedures 
  • Integumentary (skin and tissue) procedures 

Once a procedure leaves the IPO list, physicians can perform it in a hospital outpatient setting when clinically appropriate. The ASC Covered Procedures List (CPL) also expands by 618 procedures in 2027, up from 560 in 2026. So a growing number of procedures previously limited to inpatient settings can now be performed in ambulatory surgical centers. 

For revenue cycle teams, this creates two areas to monitor. First, documentation and medical necessity standards shift when procedures move to outpatient settings. Second, some procedure volume may transition to ASC settings over time, so tracking service line trends will help inform financial planning.

Prior Authorization Expands to Eight New Codes

The list of HOPD services subject to prior authorization in traditional Medicare grows in 2027. CMS proposes adding eight botulinum toxin injection codes, citing procedure volume growth that it wants to review more closely under a prior authorization framework. 

Prior authorization for a limited set of HOPD services has been in place since 2020. Revenue cycle teams should prepare for: 

  • Additional pre-authorization workflows for botulinum toxin procedures 
  • Timely submission of authorization requests to support clean claim processing 
  • Documentation that clearly supports medical necessity before service delivery 

The WISeR (Wasteful and Inappropriate Service Reduction) Model, running as a six-state pilot, separately requires prior authorization for a different set of services. Prior authorization management is becoming a larger operational function in 2027, and proactive workflow planning will help teams stay ahead of it. 

What This Means for Your Revenue Cycle Operations

This rule changes more than payment rates. It affects workflow demands, documentation expectations, and financial planning across multiple service lines simultaneously. Starting your preparation now gives your team time to model impacts, update processes, and engage in the comment period before the final rule takes effect. 

Revenue Cycle Priorities to Address Before January 2027

Model your 340B financial position. If your hospital participates in the 340B program, run financial models based on the ASP-33.4% rate. Understand how the drug payment revision and budget neutrality nondrug offset interact for your specific mix. 

Review your off-campus HOPD imaging services. Imaging-without-contrast services at off-campus locations will be reimbursed at the physician fee schedule rate under this proposal. Identify which locations provide these services and incorporate the rate change into your 2027 projections. 

Account for the nondrug payment adjustment. The 3% recovery offset applies broadly to nondrug outpatient services through 2029. Model the dollar impact across your highest-volume APCs. 

Update prior authorization workflows. Add the eight new botulinum toxin codes to your pre-authorization tracking. Training front-end staff before the rule takes effect reduces the risk of authorization gaps. 

Prepare for IPO list expansion. As 638 more procedures become outpatient-eligible, review billing and coding processes and confirm that documentation meets outpatient medical necessity standards for newly eligible procedures. 

Engage with the price transparency RFI. CMS seeks public input on standardizing hospital pricing data. Revenue cycle and compliance leaders should review the request and consider submitting comments before the August 31 deadline.

2026 vs. 2027 Key Payment Changes at a Glance

Payment Element CY 2026 CY 2027 Proposed
Base OPPS payment update 2.9% 2.4%
340B drug payment rate ASP+6% ASP-33.4%
340B remedy offset 0.5% per year 3% per year
Site-neutral services Clinic visits + drug admin Clinic visits, drug admin + imaging without contrast
IPO procedures removed 285 638
ASC CPL expansion +560 procedures +618 procedures
Prior auth additions Prior list +8 botulinum toxin codes
Net average payment change ~2.0% ~1.9%

What Comes Next

Comments on the proposed rule are due August 31, 2026. CMS will review those comments and issue the final rule in November 2026, with changes taking effect January 1, 2027. Hospital associations, advocacy groups, and individual health systems all have standing to submit comments. The 340B rate revision, imaging site-neutral expansion, and accelerated nondrug recovery timeline are all areas where hospitals can provide data and perspective to inform the final rule. CMS may adjust specific provisions between the proposed and final rule, so monitoring the November release and refreshing your financial models at that point is an important step in your planning process.

READY FOR 2027?

Keep your revenue cycle moving as Medicare payment rules change.

Similar blogs